Table 1.
Characteristics of the tissues used for genomic tests.
| Characteristics | Systemic Lymph Node Dissection | Lobe-Specific Lymph Node Dissection | p |
|---|---|---|---|
| n = 265 | n = 534 | ||
| Age (years old), | 66 | 68 | <0.01 |
| median (IQR) | (63–74) | (60–71) | |
| Sex, male (%) | 157 (59.2%) | 328 (61.4%) | 0.55 |
| Smoking history, | 30.0 | 33.9 | 0.68 |
| pack-year (median, IQR) | (0–51.0) | (0–50.0) | |
| Carcinoembryonic antigen (ng/mL) | 9.4 | 8.3 | 0.11 |
| median, IQR | (6.2–18.4) | (6.3–14.5) | |
| Clinical stage n (number, %) | <0.01 | ||
| cN0 | 164 (61.9%) | 407 (76.2%) | |
| cN1-2 | 101 (38.1%) | 127 (23.8%) | |
| Histology (number, %) | 0.29 | ||
| Adenocarcinoma | 183 (69.1%) | 388 (72.7%) | |
| Squamous | 48 (18.1%) | 86 (16.1%) | |
| Others | 34 (12.8%) | 60 (11.2%) | |
| Surgical approach (number, %) | <0.01 | ||
| Thoracoscopy | 25 (9.4%) | 127 (23.8%) | |
| Thoracotomy | 240 (90.6%) | 407 (76.2%) | |
| Type of procedures (number, %) | <0.01 | ||
| Lobectomy | 235 (88.7%) | 529 (99.1%) | |
| Pneumonectomy/Bilobectomy | 30 (11.3%) | 5 (0.9%) | |
| Adjuvant chemotherapy ± Radiotherapy | <0.01 | ||
| (yes, %) | 139 (52.5%) | 117 (21.9%) | |
| Pathological stage | <0.01 | ||
| IA1/IA2/IA3/IB | 5/19/16/35 | 13/79/47/133 | |
| IIA/IIB | 8/60 | 28/90 | |
| IIIA/IIIB | 101/21 | 115/19 | |
| Mutation status | <0.01 | ||
| EGFR or ALK positive | 106 | 148 | |
| No mutations or uninformative | 159 | 386 |
IQR, interquartile range; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase.